Good
Partially Aligned
Patient Risk:
Moderate
Summary
Many mechanistic and indication-related claims are supported by the provided label excerpts (mechanism of action, LDL reduction concept, and cardiovascular risk reduction indications). However, multiple safety-related, dosing/strength, pediatric age range, and comparative study-statistic claims are unsupported because the supplied label text does not include the specific details (e.g., side effect frequency claims for muscle pain/liver damage/high blood sugar as 'common,' grapefruit-related 'avoid' instruction magnitude, specific study percentages/average LDL decreases, FDA approval year/patent statements, and children >10 indication language).
Category Scores
Accurate Statements
Lipitor (atorvastatin) inhibits the enzyme HMG-CoA reductase responsible for cholesterol production in the liver.
Label 12.1 Mechanism of Action: “LIPITOR is a … inhibitor of HMG-CoA reductase … the … enzyme … converts … to mevalonate, a precursor of sterols, including cholesterol.”
By blocking HMG-CoA reductase, Lipitor reduces cholesterol produced in the liver.
Label 12.1 Mechanism of Action: “In animal models, LIPITOR lowers … by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver …”
Lipitor reduces low-density lipoprotein (LDL) or “bad” cholesterol levels in the blood.
Label 12.1 Mechanism of Action: “LIPITOR reduces … total-C, LDL-C …” and “LIPITOR lowers plasma cholesterol and lipoprotein levels …”
Lipitor reduces LDL cholesterol levels.
Label 12.1 Mechanism of Action: “LIPITOR reduces total-C, LDL-C …”
Lipitor can help to slow down the buildup of plaque in the arteries.
Label 12.1 Mechanism of Action includes linkage between lowered atherogenic lipoproteins (e.g., LDL-C/apo B) and atherosclerosis promotion; no explicit phrase 'slow plaque buildup' is quoted, but the label supports that elevated LDL promotes atherosclerosis and that LIPITOR reduces LDL/apo B.
Lipitor can reduce the risk of heart disease.
Label 1.1 Prevention of Cardiovascular Disease: LIPITOR indicated to reduce myocardial infarction and other CHD-related outcomes; label text ties these outcomes to CHD risk reduction.
Lipitor can reduce the risk of stroke.
Label 1.1 Prevention of Cardiovascular Disease: “Reduce the risk of stroke” (adult multiple risk factors and in type 2 diabetes populations).
Lipitor is available in various strengths, including 10 mg, 20 mg, 40 mg, and 80 mg tablets.
Label 3 Dosage Forms and Strengths: “White, elliptical, film-coated tablets containing 10, 20, 40, and 80 mg atorvastatin calcium.”
Unsupported Statements
A study in JAMA found patients taking Lipitor experienced a significant reduction in LDL cholesterol levels compared to placebo.
The supplied label excerpts do not mention a JAMA study or provide this placebo-comparator LDL result.
A study in the New England Journal of Medicine found Lipitor reduced the risk of cardiovascular events including heart attacks and strokes by 21%.
The supplied label excerpts do not mention a New England Journal of Medicine study or a 21% reduction figure.
A study in the Journal of Clinical Lipidology found patients taking Lipitor experienced a significant reduction in LDL cholesterol levels, with an average decrease of 45.6% after 12 weeks of treatment.
The supplied label excerpts do not mention this journal, 12-week timepoint, or 45.6% LDL decrease.
Common side effects of Lipitor include muscle pain.
The label provided lists adverse reactions by incidence categories in clinical trials, but does not support 'common' as a blanket classification for 'muscle pain' specifically; it does report myalgia/myopathy-related and other reactions, but the AI claim uses a general 'common side effects include muscle pain' wording without the label's specified framing.
Common side effects of Lipitor include liver damage.
The label provided discusses liver enzyme abnormalities and hepatitis/cholestasis as adverse reactions, but does not directly state 'liver damage' as a 'common side effect.'
Common side effects of Lipitor include increased blood sugar levels.
The label provided lists “hyperglycemia” among other adverse reactions, but does not support it being 'common' using the AI's wording.
Rare but serious side effects of Lipitor include rhabdomyolysis.
The label provided states rhabdomyolysis is a serious adverse reaction discussed in Warnings and Precautions; however, the AI claim asserts 'rare but serious' without label-provided rarity quantification.
Rhabdomyolysis is characterized by muscle damage and kidney failure.
The supplied label excerpt states “rhabdomyolysis with acute renal failure secondary to myoglobinuria,” but does not define rhabdomyolysis characterization as 'muscle damage and kidney failure.'
Lipitor can interact with blood thinners.
The supplied label excerpt specifically mentions warfarin and states no clinically significant effect on prothrombin time; it does not support the broader claim without nuance.
Lipitor can interact with certain antibiotics.
While the label excerpt includes clarithromycin (an antibiotic) as a strong CYP3A4 inhibitor increasing risk, it does not support 'certain antibiotics' as a general category.
Lipitor can interact with antifungals.
The label excerpt explicitly mentions azole antifungals increasing risk of myopathy/rhabdomyolysis; however, the AI claim is general ('antifungals') and not limited to the label-specified category.
Patients taking Lipitor should avoid consuming grapefruit or grapefruit juice.
The supplied label excerpt describes grapefruit juice increasing atorvastatin concentrations and notes excessive consumption (>1.2 liters/day), but it does not explicitly provide a directive to 'avoid' grapefruit/juice.
Consuming grapefruit or grapefruit juice with Lipitor can increase the risk of side effects.
The supplied label excerpt states grapefruit components inhibit CYP3A4 and can increase plasma concentrations, especially with excessive grapefruit juice consumption; it does not state 'increase the risk of side effects' in those terms.
Lipitor was approved by the FDA in 1997.
No FDA approval year is provided in the supplied label excerpts.
Lipitor was patented by Pfizer in 1996.
No patent history is provided in the supplied label excerpts.
The patent for Lipitor expired in 2011.
No patent expiration details are provided in the supplied label excerpts.
The patent for the 80 mg strength of Lipitor expired in 2016.
No strength-specific patent expiration details are provided in the supplied label excerpts.
Generic versions of Lipitor are available.
The supplied label excerpts do not address availability of generics.
Contradictions
Low
AI Statement
Lipitor was approved by the FDA in 1997.
Label Reference
Not contradicted by the provided excerpts (the label excerpts do not include an approval date).
Important Omissions
For prevention-of-cardiovascular-disease claims, the label indicates specific endpoints (myocardial infarction, stroke, revascularization/angina, hospitalization for CHF in certain CHD populations), but the AI claims are more general (e.g., 'reduce risk of heart disease') without listing the label-specific outcomes or population qualifiers.
Importance:
Moderate
Drug-interaction statements are not aligned with label-level specifics (e.g., warfarin: 'no clinically significant effect on prothrombin time' is stated in the excerpt; grapefruit: excess consumption threshold >1.2 liters/day is mentioned).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported generalizations about contraindications/warnings, side-effect frequency/definitions, and interaction instructions (e.g., 'avoid grapefruit') could mislead on safety monitoring/precautions, even though several mechanistic and specific interaction risk concepts are partially supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims (study statistics/publications, safety side-effect wording and categorizations, grapefruit advice wording, anticoagulant/antibiotic/antifungal generalizations, and FDA approval/patent/generic availability details) are not supported by the provided label excerpts.
Suggested Improvement
Restrict statements to what is explicitly supported in the provided label sections: (1) use label-specified indication language and endpoints with population qualifiers, (2) for interactions, use label-listed agents/categories and grapefruit threshold language, (3) for adverse reactions, avoid 'common'/'rare' and definitions not present in the excerpt, and (4) remove non-label patent/FDA-year/generic-availability and journal-study-statistic claims unless the label excerpts include them.